HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
(Date:5/27/2015)... (PRWEB) May 27, 2015 Allred Dental located ... help patients - who need extensive dental treatment - understand ... treatment options customized for their problems. , Dr. Jeff Allred ... visual presentation of the assessment of the patient’s oral health ... which can treat their oral health problems. , “The dental ...
(Date:5/27/2015)... 27, 2015 Black Book Rankings, ... surveys in the multiple services and software industries, ... the highest ranked Electronic Health and Medical Record ... special research focus on implemented EHR users, Black ... vendors with the highest scores in client experience ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 The MedSpa ... three FDA-approved dermal filler treatments in Abilene, Texas: Xeomin®, ... reduce the appearance of glabellar lines, better known as ... Belotero Balance® is designed to treat smoker’s lines around ... the chin, while Radiesse® improves the appearance of smile ...
(Date:5/27/2015)... Mountain View, CA (PRWEB) May 27, 2015 ... Napa Valley will be able to reach for Organic Coconut ... 2015. Coco Libre will be available at VIP areas, artist ... will also be available at area hotels and on festival ... as a partner this year,” said Noa Elan, Director of ...
(Date:5/27/2015)... Genius Monkey is pleased to announce that ... they have boosted sales for the Utah Honda Dealers ... for seven Utah-based dealers. , Until recently, the ... media. In 2014 the Utah Honda dealers changed their ... Monkey , shifted their marketing campaigns more towards targeted ...
Breaking Medicine News(10 mins):Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "2015 Strategies in ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... strategic overview of the orthopedics market, including ... and product categories. , ,In addition, the ...
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "North ... Forecasts (2014 - 2019)"  report to ... ,  , ,Mammography is a detailed type ... system to inspect breasts. A mammography exam, ...
(Date:5/27/2015)... -- OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to ... series of diverse complications arising from the presence of ... which cause a rapidly progressing hyperactive host immune response ... depending on disease severity. The syndrome places a major ... marketplace, which for the purposes of this report is ...
Breaking Medicine Technology:Global Orthopedics Market Strategies 2015 2North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
Cached News: